NSCLC: Safety Outcomes from HERTHENA-Lung01
Medical oncologists discuss the toxicity profile of patritumab deruxtecan and the safety outcomes from HERTHENA-Lung01 in non–small cell lung cancer.
Source: onclive.com
Page 36 - Nsclc News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Nsclc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Nsclc Today - Breaking & Trending Today
Role of HER3-DXd in Advanced NSCLC Treatment Landscape
Clinical insights on where patritumab deruxtecan might fit in the treatment paradigm for patients with advanced non–small cell lung cancer.
Source: onclive.com
Zenocutuzumab Generates Durable Responses in Advanced NRG1+ NSCLC
Zenocutuzumab elicited clinical activity with a tolerable safety profile in patients with advanced non–small cell lung cancer harboring NRG1 fusions, including those with prior afatinib exposure, according to findings from the ongoing, phase 1/2 eNRGy trial.
Source: onclive.com
COMING SOON: Dato-DXd vs Docetaxel in Previously Treated Advanced/Metastatic Non–Small Cell Lung Cancer: Results of the Randomized Phase III Study TROPION-Lung01
Aaron Lisberg, MD, provides a look at an upcoming Rapid Readout program looking at the results of the TROPION-Lung01 study investigating Dato-DXd in previously treated patients with advanced/metastatic NSCLC.
Source: onclive.com
COMING SOON: Precision Oncology: Molecular Genotyping and Optimal Treatment of Metastatic Nonsquamous NSCLC
Expert oncologist Charu Aggarwal, MD, MPH, shares her excitement for an upcoming program centered on molecular genotyping and its role in the setting of metastatic nonsquamous non–small cell lung cancer management.
Source: onclive.com